406502-38-3Relevant articles and documents
Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: Metabolism-directed optimization studies towards orally bioavailable derivatives
Vergne, Fabrice,Bernardelli, Patrick,Lorthiois, Edwige,Pham, Nga,Proust, Emmanuelle,Oliveira, Chrystelle,Mafroud, Abdel-Kader,Ducrot, Pierre,Wrigglesworth, Roger,Berlioz-Seux, Fran?oise,Coleon, Francis,Chevalier, Eric,Moreau, Fran?ois,Idrissi, Moulay,Tertre, Anita,Descours, Arnaud,Berna, Patrick,Li, Mei
, p. 4615 - 4621 (2004)
The synthesis and optimization of pharmacokinetic parameters of structurally novel small PDE7 inhibitors is discussed.
New thiadiazoles and their use as phosphodiesterase-7 inhibitors
-
Page 18, (2010/01/31)
The invention provides 1,3,4-thiadiazoles having the following formula (I): in which,R1 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl or a polycyclic group, optionally substituted,R2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl or aryl optionally substituted,R3 is X2-R'3, in which X2 is a binding group and R'3 is cycloalkyl, heterocycloalkyl, cycloalkenyl, aryl, heteroaryl, or a polycyclic group; optionally substituted, or their pharmaceutically acceptable derivatives, the process for their preparation and their use for the manufacture of a medicament for the treatment of disorders for which a treatment by a PDE7 inhibitor is relevant.
